Following this month’s Rare Disease Day, join Canada 2020 for an event bringing together industry experts, policy makers, and patient advocates to discuss Canada’s rare disease drug strategy, and how best to plan for the future.
The upcoming year could be a momentous one for Canadians impacted by rare diseases. In 2019, the Government of Canada committed to developing a National Strategy for Drugs for Rare Diseases, with an initial commitment of $1 billion over two years beginning in 2022-23. This presents a real opportunity for Canadian patients who have struggled to get access to affordable treatment.
Following this month’s Rare Disease Day, join Canada 2020 for an event bringing together industry experts, policy makers, and patient advocates to discuss Canada’s rare disease drug strategy, and how best to plan for the future.
Featured Participants
-
Durhane Wong-Rieger
President CEO, Canadian Organization for Rare Disorders & Institute for Optimizing Health Outcomes
Biography -
Marcel Saulnier
Associate, Santis Health
-
Suzanne McGurn
President and Chief Executive Officer, CADTH
-
Dr. Michelle Mujoomdar
Director, Specialty Pharmaceuticals, Health Canada
-
Michelle Boudreau
Executive Director, Office of Pharmaceutical Management Strategies, Health Canada
-
Whitney Goulstone
Executive Director, Canadian Immunodeficiencies Patient Organization
-
Dr. Stephen Betschel
Departmental Division Director of Clinical Immunology, Department of Medicine, University of Toronto
-
Jo De Cock
Senior Adviser, National Institute of Health and Disability Insurance (INAMI-RIZIV)
-
Rute Fernandes
Executive Director, Takeda Canada